Home / Arts and Entertainment / Blumhouse's Uneven Horror Reign: Hits, Misses, and the Fight to Reclaim the Spotlight
Blumhouse's Uneven Horror Reign: Hits, Misses, and the Fight to Reclaim the Spotlight
20 Oct
Summary
- Blumhouse's horror hits have grossed over $2 billion, but recent releases have underperformed
- Competition from other studios like A24, Warner Bros., and Neon is carving into Blumhouse's market share
- Blumhouse's shift to rebooting classic horror franchises has led to mixed results

Over the past few years, Blumhouse Productions has experienced a rollercoaster ride in the horror genre. The company, known for its low-budget, high-margin horror hits, has seen tremendous success with franchises like Paranormal Activity, Insidious, and The Purge, grossing over $2 billion collectively. However, since the beginning of 2024, Blumhouse has been on a cold streak, releasing a string of box office disappointments.
In 2025, the company's entire slate, including films like Wolf Man, Woman in the Yard, and Drop, have underperformed financially. This has led some industry observers to wonder if Blumhouse's founder, Jason Blum, is losing his ability to connect with audiences. The competition from other horror-focused studios, such as A24's Talk to Me, Warner Bros.' Weapons, and Neon's Longlegs, has been increasingly carving into Blumhouse's market share.
Blumhouse's recent shift towards rebooting classic horror franchises, such as The Exorcist and Halloween, has also yielded mixed results. While the 2018 Halloween reboot was a major success, the company's $400 million acquisition of the Exorcist franchise has yet to pay off, with the 2023 film The Exorcist: Believer receiving poor reviews and underperforming at the box office.
Despite these challenges, Blumhouse has shown signs of a potential comeback. The company's latest release, Black Phone 2, debuted at the top of the box office, earning $27.3 million in its opening weekend. However, with the broader box office still struggling to recover from the impact of the COVID-19 pandemic, Blumhouse's future dominance in the horror genre remains uncertain.